Improved bioavailability of levodopa using floatable spray-coated microcapsules for the management of Parkinson’s disease
Oral administration of levodopa (LD) is the gold standard in managing Parkinson’s disease (PD). Although LD is the most effective drug in treating PD, chronic administration of LD induces levodopa-induced dyskinesia. A continuous and sustained provision of LD to the brain could, therefore, reduce pe...
Main Authors: | Baek, Jong-Suep, Tee, Jie Kai, Pang, Yi Yun, Tan, Ern Yu, Lim, Kah Leong, Ho, Han Kiat, Loo, Joachim Say Chye |
---|---|
Other Authors: | School of Materials Science & Engineering |
Format: | Journal Article |
Language: | English |
Published: |
2019
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/92269 http://hdl.handle.net/10220/49468 |
Similar Items
-
Discinesias induzidas por levodopa em 176 pacientes com doença de Parkinson Levodopa-induced dyskinesias in 176 parkisonian patients
by: Maria Sheila G. Rocha, et al.
Published: (1995-12-01) -
Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease
by: Sharma VD, et al.
Published: (2018-04-01) -
Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence
by: Ritam Bandopadhyay, et al.
Published: (2022-04-01) -
Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease
by: Nayron Medeiros Soares, et al.
Published: (2023-01-01) -
Levodopa in the treatment of Parkinson’s disease: an old drug still going strong
by: Werner Poewe, et al.
Published: (2010-08-01)